Inflammatory myofibroblastic tumor
Revision as of 12:20, 15 July 2024 by Warner-admin (talk | contribs) (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''")
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: this is a rare cancer, see this page for more information. These are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
All lines of therapy
Crizotinib monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Gambacorti-Passerini et al. 2018 (PROFILE 1013) | 2011-03 to 2013-10 | Phase 1b, fewer than 20 pts in this subgroup (RT) |
Biomarker eligibility criteria
- ALK+
References
- PROFILE 1013: Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol. 2018 May;93(5):607-614. Epub 2018 Feb 8. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT01121588